Symptoma GmbH

  • Funded by Austrian Research Promotion Agency (FFG)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Austrian Research Promotion Agency (FFG)
  • Principal Investigator

    N/A

  • Research Location

    Austria
  • Lead Research Institution

    Symptoma GmbH
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Digital Health

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

COVID-19 Path: An artificial intelligence-based first-line defense against COVID-19: digitally screening patient via a chatbot. Symptoma has developed the world's first artificial intelligence that can reliably assess a COVID-19 risk in the context of 20,000 possible diseases. The chatbot is based on 14 years of research, has been approved as a medical product and has achieved the highest accuracy worldwide with 96.32% in two scientific studies. The aim is now to digitally screen patients for COVID-19 before visiting a doctor and thus to help hospitals enable a contactless check-in process at the entrance.